Summary of findings 3. Dalteparin compared to tinzaparin in people with cancer with VTE.
| Dalteparin initial treatment compared to tinzaparin initial treatment in people with cancer with VTE | |||||
|
P: people with cancer and a confirmed diagnosis of VTE S: inpatient/outpatient I: dalteparin initial treatment C: tinzaparin initial treatment | |||||
| Outcomes | No of participants (studies) | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects* (95% CI) | |
| Risk with tinzaparin | Risk difference with dalteparin | ||||
| Mortality follow‐up: 3 months | 113 (1 RCT) | ⊕⊕⊝⊝ Low1 | RR 0.86 (0.43 to 1.73) | Study population | |
| 237 per 1000 | 33 fewer per 1000 (135 fewer to 173 more) | ||||
| Recurrent VTE follow‐up: 3 months | 113 (1 RCT) | ⊕⊕⊝⊝ Low2 | RR 0.44 (0.09 to 2.16) | Study population | |
| 85 per 1000 | 47 fewer per 1000 (77 fewer to 98 more) | ||||
| Major bleeding follow‐up: 3 months | 113 (1 RCT) | ⊕⊕⊝⊝ Low3 | RR 2.19 (0.20 to 23.42) | Study population | |
| 17 per 1000 | 20 more per 1000 (14 fewer to 380 more) | ||||
| Minor bleeding follow‐up: 3 months | 113 (1 RCT) | ⊕⊕⊝⊝ Low4 | RR 0.82 (0.30 to 2.21) | Study population | |
| 136 per 1000 | 24 fewer per 1000 (95 fewer to 164 more) | ||||
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio; VTE: venous thromboembolism. | |||||
| GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | |||||
195% CI was consistent with the possibility for important benefit (135 per 1000 absolute reduction) and possibility of important harm (173 per 1000 absolute increase), including 25 events among included participants.
295% CI was consistent with the possibility for important benefit (77 per 1000 absolute reduction) and possibility of important harm (98 per 1000 absolute increase), including 7 events among included participants.
395% CI was consistent with the possibility for important benefit (14 per 1000 absolute reduction) and possibility of important harm (380 per 1000 absolute increase), including 3 events among included participants.
495% CI was consistent with the possibility for important benefit (95 per 1000 absolute reduction) and possibility of important harm (164 per 1000 absolute increase), including 14 events among included participants.